Study on the effectiveness of COVID-19 measures in the Netherlands The measures implemented in the Netherlands during the COVID-19 crisis were effective against the spread of the SARS-CoV-2 virus. This is the outcome of a study conducted by RIVM.
295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Key persons should be involved in policy for pandemics RIVM advises government authorities to involve ‘key persons’ in formulating policy for current and future pandemics. Results from RIVM research show that these individuals played a key role in ensuring an ongoing focus on social well-being and mental health during the COVID-19 pandemic, despite the limitations.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.